FAM163A

Summary

FAM163A (family with sequence similarity 163 member A, HGNC:28274) is a protein-coding gene on chromosome 1q25.2, encoding Protein FAM163A (Q96GL9).

Predicted to be located in membrane.

Source: NCBI Gene 148753 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 32 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_173509

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28274
Approved symbol	FAM163A
Name	family with sequence similarity 163 member A
Location	1q25.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC16664, NDSP
Ensembl gene	ENSG00000143340
Ensembl biotype	protein_coding
OMIM	611727
Entrez	148753

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000341785, ENST00000879738, ENST00000879739

RefSeq mRNA: 18 — MANE Select: NM_173509 NM_001329712, NM_001329713, NM_001329714, NM_001329715, NM_001329716, NM_001329717, NM_001329718, NM_001329719, NM_001393415, NM_001393416, NM_001393417, NM_001393418, NM_001393419, NM_001393420, NM_001393421, NM_001393422, NM_001393423, NM_173509

CCDS: CCDS1333

Canonical transcript exons

ENST00000341785 — 5 exons

Exon	Start	End
ENSE00001372978	179813076	179813190
ENSE00001381942	179812110	179812131
ENSE00001405816	179743291	179743423
ENSE00001445160	179813779	179816198
ENSE00002395650	179807798	179807888

Expression profiles

Bgee: expression breadth ubiquitous, 123 present calls, max score 91.84.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4711 / max 120.8767, expressed in 100 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6920	0.2923	64
6921	0.0864	31
6919	0.0424	16
6918	0.0183	8
6916	0.0167	3
6917	0.0150	5

Top tissues by expression

268 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	91.84	gold quality
male germ cell	CL:0000015	89.42	gold quality
pituitary gland	UBERON:0000007	84.98	gold quality
adenohypophysis	UBERON:0002196	82.41	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.61	gold quality
lateral nuclear group of thalamus	UBERON:0002736	76.51	gold quality
right testis	UBERON:0004534	76.09	gold quality
left testis	UBERON:0004533	75.65	gold quality
pons	UBERON:0000988	73.35	gold quality
testis	UBERON:0000473	73.10	gold quality
thymus	UBERON:0002370	68.91	gold quality
islet of Langerhans	UBERON:0000006	68.42	gold quality
prefrontal cortex	UBERON:0000451	67.54	gold quality
right frontal lobe	UBERON:0002810	63.22	gold quality
muscle layer of sigmoid colon	UBERON:0035805	62.59	gold quality
pigmented layer of retina	UBERON:0001782	62.54	gold quality
cingulate cortex	UBERON:0003027	62.16	gold quality
anterior cingulate cortex	UBERON:0009835	62.16	gold quality
frontal cortex	UBERON:0001870	61.99	gold quality
vermiform appendix	UBERON:0001154	61.34	gold quality
neocortex	UBERON:0001950	60.62	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	60.61	gold quality
Brodmann (1909) area 9	UBERON:0013540	60.42	gold quality
olfactory bulb	UBERON:0002264	60.17	gold quality
type B pancreatic cell	CL:0000169	59.99	gold quality
gall bladder	UBERON:0002110	58.96	gold quality
caecum	UBERON:0001153	58.02	gold quality
apex of heart	UBERON:0002098	57.23	gold quality
cerebral cortex	UBERON:0000956	55.77	gold quality
colon	UBERON:0001155	55.20	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

89 targeting FAM163A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-12130	99.75	65.47	452
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-4756-3P	99.62	66.30	1319
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-4489	99.50	65.56	785
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-4498	99.47	67.42	2360

Literature-anchored findings (GeneRIF, showing 2)

• NDSP is specifically overexpressed in neuroblastoma and actively secreted from tumor cells. Furthermore, NDSP serves as a growth factor for neuroblastoma tumor cells through activation of the ERK-mediated proliferation pathway. (PMID:19671756)
• Novel loci for ocular axial length identified through extreme-phenotype genome-wide association study in Chinese populations. (PMID:37524447)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam163aa	ENSDARG00000077470
danio_rerio	fam163ab	ENSDARG00000093021
mus_musculus	Fam163a	ENSMUSG00000015484
rattus_norvegicus	Fam163a	ENSRNOG00000024825

Protein

Protein identifiers

Protein FAM163A — Q96GL9 (reviewed: Q96GL9)

Alternative names: Cebelin, Neuroblastoma-derived secretory protein

All UniProt accessions (1): Q96GL9

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Tissue specificity. Highly expressed in neuroblastoma compared to other tissues, suggesting that it may be used as a marker for metastasis in bone marrow.

Similarity. Belongs to the FAM163 family.

RefSeq proteins (18): NP_001316641, NP_001316642, NP_001316643, NP_001316644, NP_001316645, NP_001316646, NP_001316647, NP_001316648, NP_001380344, NP_001380345, NP_001380346, NP_001380347, NP_001380348, NP_001380349, NP_001380350, NP_001380351, NP_001380352, NP_775780* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029379	FAM163	Family
IPR040281	FAM163A	Family

Pfam: PF15069

UniProt features (2 total): chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96GL9-F1	58.54	0.10

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 56 (showing top): BENPORATH_ES_WITH_H3K27ME3, chr1q25, MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, MIKKELSEN_MCV6_HCP_WITH_H3K27ME3, MIKKELSEN_MEF_HCP_WITH_H3K27ME3, GSE13522_CTRL_VS_T_CRUZI_G_STRAIN_INF_SKIN_DN, MIR6867_5P, MIR4492, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2, MIR4283, MIR185_3P, MIR6752_3P, MIR6814_5P, MIR571

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

516 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAM163A	LRP10	Q7Z4F1	553
FAM163A	DCAF13	Q9NV06	480
FAM163A	CST9L	Q9H4G1	474
FAM163A	TOR1AIP2	Q8NFQ8	468
FAM163A	LRP4	O75096	466
FAM163A	MAMDC2	Q7Z304	462
FAM163A	CSKMT	A8MUP2	448
FAM163A	V9GXZ4	V9GXZ4	435
FAM163A	FRAS1	Q86XX4	428
FAM163A	TOR1AIP1	Q5JTV8	422
FAM163A	TNNI3K	Q59H18	419
FAM163A	PVRIG	Q6DKI7	418
FAM163A	TAFA1	Q7Z5A9	413
FAM163A	CACFD1	Q9UGQ2	408
FAM163A	CCBE1	Q6UXH8	405

IntAct

75 interactions, top by confidence:

A	B	Type	Score
GET3	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
RWDD2B	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
TMEM179B	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
GAD2	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
CRYAA	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	ATN1	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	F13A1	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	FGFR3	psi-mi:“MI:0915”(physical association)	0.560
GRIN2C	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	GSN	psi-mi:“MI:0915”(physical association)	0.560
UBE2K	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	PECAM1	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	VIM	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	WFS1	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	GIPC1	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
FAM163A	RNF11	psi-mi:“MI:0915”(physical association)	0.560
UBQLN1	FAM163A	psi-mi:“MI:0915”(physical association)	0.560
HTT	FAM163A	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (23): WDR47 (Affinity Capture-MS), YWHAZ (Affinity Capture-MS), YWHAG (Affinity Capture-MS), YWHAE (Affinity Capture-MS), YWHAB (Affinity Capture-MS), FAM163A (Two-hybrid), RWDD2B (Two-hybrid), TMEM179B (Two-hybrid), WDR47 (Affinity Capture-MS), YWHAG (Affinity Capture-MS), YWHAZ (Affinity Capture-MS), CRTAP (Affinity Capture-MS), KLHL22 (Affinity Capture-MS), FAM163A (Affinity Capture-MS), TRIM68 (Affinity Capture-MS)

ESM2 similar proteins: A1L3I3, A2A699, A2RV66, A4IG66, A6NL88, A6QPA0, A7MC48, A8MVW0, B3DHW5, B4DS77, D3ZD05, D3ZZP4, E9Q0S6, G3V735, J3QNX5, O94983, P0C2L3, Q08E39, Q1LZH7, Q2WFL8, Q3UH99, Q3UIL6, Q5BJT1, Q5BLC7, Q5DU25, Q5JU85, Q5SWY7, Q63ZY3, Q69YU3, Q6IQ23, Q6UWI4, Q6ZSJ9, Q7T0Z7, Q80Y50, Q8BUM6, Q8BX02, Q8C3Q5, Q8C8T7, Q8CAA5, Q8IUW5

Diamond homologs: P0C2L3, Q0VFM5, Q8BUM6, Q8CAA5, Q96GL9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1980 predictions. Top by Δscore:

Variant	Effect	Δscore
1:179807889:G:GG	donor_gain	1.0000
1:179809405:GGAAT:G	donor_gain	1.0000
1:179809406:GAATG:G	donor_gain	1.0000
1:179809407:A:T	donor_gain	1.0000
1:179809417:C:G	donor_gain	1.0000
1:179813777:A:AG	acceptor_gain	1.0000
1:179813778:G:GG	acceptor_gain	1.0000
1:179813778:GT:G	acceptor_gain	1.0000
1:179743390:G:GT	donor_gain	0.9900
1:179743452:G:T	donor_gain	0.9900
1:179807796:AG:A	acceptor_gain	0.9900
1:179807797:GG:G	acceptor_gain	0.9900
1:179807887:ACGT:A	donor_loss	0.9900
1:179807888:CGTA:C	donor_loss	0.9900
1:179807889:G:GA	donor_loss	0.9900
1:179807890:T:TG	donor_loss	0.9900
1:179807891:A:AG	donor_loss	0.9900
1:179807893:GT:G	donor_gain	0.9900
1:179809447:G:GG	donor_gain	0.9900
1:179812132:G:GG	donor_gain	0.9900
1:179813075:GA:G	acceptor_gain	0.9900
1:179813776:C:G	acceptor_gain	0.9900
1:179813776:CA:C	acceptor_loss	0.9900
1:179813777:A:G	acceptor_loss	0.9900
1:179813778:GTA:G	acceptor_gain	0.9900
1:179813778:GTATT:G	acceptor_gain	0.9900
1:179743907:G:GT	donor_gain	0.9800
1:179743907:G:T	donor_gain	0.9800
1:179807792:TGGCA:T	acceptor_loss	0.9800
1:179807793:GGCA:G	acceptor_loss	0.9800

AlphaMissense

1074 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:179813126:G:A	G10D	0.996
1:179813125:G:C	G10R	0.994
1:179813150:T:A	L18H	0.994
1:179813128:G:A	G11R	0.992
1:179813128:G:C	G11R	0.992
1:179813138:C:A	A14D	0.992
1:179813155:T:C	C20R	0.989
1:179813173:T:C	C26R	0.989
1:179813120:T:A	I8N	0.987
1:179813129:G:A	G11E	0.987
1:179813107:G:A	G4R	0.986
1:179813107:G:C	G4R	0.986
1:179813114:T:A	V6D	0.986
1:179813150:T:G	L18R	0.986
1:179814175:A:C	S164R	0.986
1:179814177:T:A	S164R	0.986
1:179814177:T:G	S164R	0.986
1:179813153:T:A	L19H	0.985
1:179813147:T:A	I17N	0.983
1:179813153:T:G	L19R	0.983
1:179813183:G:T	R29M	0.983
1:179813179:T:C	C28R	0.982
1:179813141:C:A	T15K	0.980
1:179813102:C:T	T2I	0.976
1:179813108:G:A	G4E	0.976
1:179813181:C:G	C28W	0.976
1:179813180:G:A	C28Y	0.975
1:179813120:T:G	I8S	0.974
1:179813120:T:C	I8T	0.972
1:179813135:T:G	L13R	0.972

dbSNP variants (sampled 300 via entrez): RS1000062655 (1:179781370 C>T), RS1000066720 (1:179811085 A>C,T), RS1000088794 (1:179806689 G>A,C,T), RS1000097335 (1:179766230 A>G), RS1000143810 (1:179765071 T>C), RS1000150240 (1:179739345 A>G), RS1000159423 (1:179794130 G>C,T), RS1000177829 (1:179789311 A>G), RS1000255495 (1:179743950 G>T), RS1000297288 (1:179774411 A>G), RS1000307480 (1:179800558 T>G), RS1000314797 (1:179782756 G>A), RS1000361383 (1:179775015 G>A,C), RS1000419080 (1:179746363 T>A,C), RS1000446428 (1:179765990 G>A)

Disease associations

OMIM: gene MIM:611727 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): endometriosis (MONDO:0005133)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0030127	Endometriosis

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST008810_37	Smoking initiation (ever regular vs never regular)	1.000000e-07
GCST009441_11	Age-related cognitive decline (memory) (slope of z-scores)	3.000000e-06
GCST90002394_91	Monocyte percentage of white cells	4.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005670	smoking initiation
EFO:0007710	cognitive decline measurement
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D004715	Endometriosis	C12.050.351.500.163; C12.100.250.163

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, decreases methylation	2
Aflatoxin B1	decreases methylation	2
bisphenol A	decreases methylation	1
arsenite	increases methylation	1
aflatoxin B2	increases methylation	1
entinostat	increases expression	1
(+)-JQ1 compound	affects expression, increases reaction	1
Resveratrol	decreases expression, affects cotreatment	1
Fulvestrant	increases methylation	1
Panobinostat	increases reaction, affects expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Copper	decreases expression, affects cotreatment	1
Diethylhexyl Phthalate	decreases expression	1
Folic Acid	decreases expression	1
Hydralazine	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Dronabinol	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00286351	PHASE4	COMPLETED	Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis
NCT00621179	PHASE4	COMPLETED	Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
NCT00625950	PHASE4	COMPLETED	Endometriosis Patients Undergoing Quinagolide Treatment
NCT00654524	PHASE4	UNKNOWN	Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis
NCT00735852	PHASE4	COMPLETED	Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women
NCT00844012	PHASE4	UNKNOWN	Continuous Postoperative Use of Low-Dose Combined Oral Contraceptivesfor for Endometriosis-Related Chronic Pelvic Pain
NCT01056042	PHASE4	COMPLETED	Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain
NCT01581359	PHASE4	COMPLETED	The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis
NCT01682642	PHASE4	COMPLETED	The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
NCT01769781	PHASE4	COMPLETED	Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
NCT01779232	PHASE4	COMPLETED	Danazol Treatment in Endometriosis Women Before IVF
NCT02158845	PHASE4	COMPLETED	Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis
NCT02165917	PHASE4	UNKNOWN	Study to Compare Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesion Barrier
NCT02213081	PHASE4	COMPLETED	Ulipristal for Endometriosis-related Pelvic Pain
NCT02214550	PHASE4	COMPLETED	Chronic Pain Risk Associated With Menstrual Period Pain
NCT02385448	PHASE4	UNKNOWN	Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery
NCT02387931	PHASE4	COMPLETED	Supplementation in Adolescent Girls With Endometriosis
NCT02393482	PHASE4	UNKNOWN	Psychological Impact of Amenorrhea in Women With Endometriosis
NCT02427386	PHASE4	COMPLETED	Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis
NCT02475564	PHASE4	COMPLETED	Resveratrol for Pain Due to Endometriosis
NCT02480647	PHASE4	COMPLETED	Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis
NCT02534688	PHASE4	COMPLETED	Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients
NCT02812186	PHASE4	COMPLETED	Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery
NCT04218487	PHASE4	UNKNOWN	Xuefu-Zhuyu Capsule for the Treatment of Qizhi Xueyu Zheng (Qi Stagnation and Blood Stasis Syndrome)
NCT04554693	PHASE4	ACTIVE_NOT_RECRUITING	The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery
NCT04942015	PHASE4	UNKNOWN	Honghuaruyi Wan for Endometriosis Dysmenorrhea
NCT05013242	PHASE4	UNKNOWN	Goserline Acetate VS Dienogest in Endometriosi
NCT05059626	PHASE4	RECRUITING	Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee
NCT05331053	PHASE4	TERMINATED	MicroRNA Activation of LOX-1 Mechanisms in Endometriosis
NCT05560230	PHASE4	COMPLETED	Intraoperative Clonidine for Postoperative Pain Management in Patients Undergoing Surgical Treatment for Endometriosis
NCT05962034	PHASE4	RECRUITING	Thromboxane Function in Women With Endometriosis
NCT06523530	PHASE4	RECRUITING	Effect of a GnRH Analog on Hepatic Steatosis
NCT06543550	PHASE4	RECRUITING	Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis
NCT06577233	PHASE4	RECRUITING	Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis
NCT06951802	PHASE4	RECRUITING	Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine
NCT07144904	PHASE4	NOT_YET_RECRUITING	Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis
NCT07182032	PHASE4	WITHDRAWN	Ketamine in Central Sensitization
NCT07532876	PHASE4	ENROLLING_BY_INVITATION	Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain
NCT00225186	PHASE3	COMPLETED	Safety and Efficacy of SH T00660AA in Treatment of Endometriosis
NCT00225199	PHASE3	COMPLETED	Efficacy and Safety of SH T00660AA in Treatment of Endometriosis